Clinical trial Recruiting at 1 site Observational Ages 18 and up

Comparing mobile health screening to traditional methods for early detection of oral cancer in rural Varanasi.

Official title: The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study

Run by Memorial Sloan Kettering Cancer Center · NCT06535867 · Data updated 2026-11-12

This study tests if using mobile health screenings can help find oral cancer earlier than traditional methods for people living in rural Varanasi.

More Smoking trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment5122 (estimated)
SponsorMemorial Sloan Kettering Cancer Center
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedJuly 30, 2024
Main results expectedJuly 30, 2031
Study endsJuly 30, 2031
Registry record updatedMay 22, 2026
Trial IDNCT06535867 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals over 18 with habits such as smoking or chewing betel leaf, or those over 40 regardless of habits.

Probably not a fit

Patients already diagnosed with oral cancer or undergoing treatment for it will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of mobile health (mHealth) screening compared to conventional screening methods for the early detection of oral potentially malignant disorders and oral cancer among the rural population of Varanasi. It aims to enhance awareness of oral cancer and improve the diagnostic knowledge of frontline health providers. The study includes long-term surveillance to help downstage oral cancer in India, focusing on individuals with specific risk factors and symptoms. Participants will be monitored for signs of oral cancer and pre-cancerous lesions.

Why it matters

Potential benefit: If successful, this approach could lead to earlier detection of oral cancer, improving patient outcomes and survival rates.

How similar studies have gone: Other studies have shown promise in using mobile health technologies for cancer screening, suggesting a potential for success in this novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Positive for any one or more of the following:

* All individuals aged above 18 years positive for habits (smoking and smokeless tobacco, chewing betel leaf, areca nut, paan masala, and/or regular use of alcohol)
* Clinical signs/symptoms (non-healing ulcers, white/ red/red \& white patches in the mouth, restriction of mouth opening and swelling of the neck)
* All individuals aged above 40 irrespective of habit/oral lesions

Exclusion Criteria:

* Individuals already diagnosed with oral cancer and undergoing treatment for oral cancer
* Under treatment for tuberculosis or suffering from any acute illness/ debilitating systemic disorders

Where it's running

  • Memorial Sloan Kettering Cancer Center (All protocol activites)
    New York, New York, United States
    Recruiting

Study contacts

  • Principal investigator: Milind Rajadhyaksha, PhD — Memorial Sloan Kettering Cancer Center
  • Study coordinator: Milind Rajadhyaksha, PhD
  • Email: rajadhym@mskcc.org
  • Phone: 646-608-2364

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.